Antengene Announces Abstracts on Twelve Clinical Studies of Selinexor Selected by EHA 2021

SHANGHAI and HONG KONG, June 1, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology...

from PR Newswire: https://ift.tt/2Rixcrm